Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 27 peer-reviewed journal articles Updated
Endocrinology

What Are Long-Term Effects of CAH Steroid Overtreatment?

At a Glance

Taking more steroid replacement than needed for classic CAH over time can contribute to weight gain, insulin resistance, high blood pressure, cholesterol changes, and weaker bones. Never lower the dose yourself; an endocrinologist must balance adrenal-crisis protection with long-term safety.

In this answer

5 sections

01

Possible Signs of Glucocorticoid Excess

02

Metabolic Changes and Weight Gain

03

Cardiovascular Risks and Hypertension

04

Bone Health and Osteoporosis

05

Balancing Your Treatment

IMPORTANT SAFETY WARNING
Never reduce, skip, or stop your glucocorticoid medication on your own. In classic CAH, your medication is life-sustaining. Stopping or lowering your dose independently can trigger an adrenal crisis, a life-threatening medical emergency [1]. Always follow your endocrinologist’s prescribed plan, which includes taking higher “stress doses” during illness or surgery, carrying an emergency hydrocortisone injection, and wearing a medical alert ID [2][3]. If you experience repeated vomiting, severe weakness, or cannot keep your medication down, seek urgent medical care [1][2].

This page primarily addresses adults with classic congenital adrenal hyperplasia (CAH) who require daily glucocorticoid replacement. Living with CAH requires balancing glucocorticoids (like hydrocortisone) to replace missing cortisol and to control excess androgens (male sex hormones that both men and women produce).

Taking too much hydrocortisone over a long period can lead to iatrogenic hypercortisolism (sometimes called iatrogenic Cushing syndrome)—having too much cortisol in the body due to medical treatment [4]. While finding the lowest effective prescribed dose is important, your risk for side effects depends on your lifetime exposure, dose, and individual health factors [5][4].

Possible Signs of Glucocorticoid Excess

Overtreatment does not always cause immediate symptoms, but physical signs can develop over time and are monitored during your physical examination [6]. Possible signs include:

  • Unexplained weight gain, especially around the middle (central adiposity) [7][8]
  • A rounded facial appearance, thin skin, or easy bruising [6]
  • Muscle weakness [6]

If you notice these changes, discuss them with your care team, but do not self-adjust your medication [6].

Metabolic Changes and Weight Gain

A common long-term side effect of receiving too much hydrocortisone is changes in your metabolism. Adults with CAH often experience increased body weight and abdominal fat [7][9]. Prolonged overtreatment can also contribute to insulin resistance [10][11]. Insulin is a hormone that helps your body use sugar for energy; when you are resistant, your body must produce more insulin to keep your blood sugar normal, increasing your risk of developing type 2 diabetes [12]. However, insulin resistance and weight gain in CAH are multifactorial and can also be influenced by the disease itself, not just the medication [13][10].

Cardiovascular Risks and Hypertension

Because glucocorticoid overtreatment can affect weight and metabolism, it can also impact your cardiovascular health [7][14]. Studies show that people with CAH have higher rates of cardiovascular risk factors like hypertension (high blood pressure) and elevated cholesterol compared to the general population [10][15].

It is important to know that hydrocortisone overtreatment is only one potential cause. High blood pressure can also be driven by excessive doses of fludrocortisone (a mineralocorticoid used in salt-wasting CAH), androgen excess, age, and natural disease processes [16][14]. Managing these risks requires regular monitoring of your blood pressure, weight, fasting glucose or HbA1c, and lipid profiles [6][8].

Bone Health and Osteoporosis

Long-term exposure to high doses of glucocorticoids can weaken your bones. Some studies find that adults with CAH have, on average, a modestly lower bone mineral density (BMD) than those without the condition, particularly with prolonged glucocorticoid excess; whether fracture risk is significantly higher is less certain and can depend on other factors [17][18]. In severe cases, low BMD can lead to osteoporosis, making bones fragile [19]. Risk is also influenced by your age, biological sex, nutrition, and whether you have hypogonadism (low sex hormones) [20][21].

The type of glucocorticoid you take also matters; longer-acting synthetic medications like dexamethasone or prednisolone have been associated with a greater negative impact on bone health compared to hydrocortisone [22][23]. If your endocrinologist safely reduces your hydrocortisone dose, your bone density may stabilize or sometimes improve, though this is not guaranteed [24].

Guidelines recommend risk-based screening for bone health [18][8]. Adults with CAH should discuss with their doctor whether they need a DXA scan (dual-energy x-ray absorptiometry, a specialized x-ray that measures bone density) based on their cumulative steroid exposure, fracture history, and other risk factors [18].

Balancing Your Treatment

The goal of CAH treatment is to find the lowest effective prescribed dose of glucocorticoid that prevents adrenal crisis and controls androgens without causing long-term side effects [5][24].

Doctors now understand that strict normalization of standard lab markers—such as 17-OHP (17-hydroxyprogesterone, a precursor hormone that builds up in CAH)—is often achieved only by giving too much hydrocortisone [4][25]. A high 17-OHP result is not automatically a reason to increase your dose; targets depend on the timing of your blood draw relative to when you took your medication, other androgen markers, and clinical guidelines [6][26]. Your treatment plan must be individualized, relying on a combination of blood tests, physical health, weight, blood pressure, and how you feel [6][27].

Common questions in this guide

What signs could mean I am getting too much steroid treatment for CAH?
Possible signs include weight gain around the middle, a rounded face, thin skin, easy bruising, and muscle weakness. These changes do not prove that your dose is too high, so discuss them with your endocrinologist instead of changing hydrocortisone yourself.
Can too much hydrocortisone in CAH raise the risk of diabetes and heart problems?
Long-term glucocorticoid excess can contribute to weight gain and insulin resistance, which may raise the risk of type 2 diabetes. People with CAH can also have high blood pressure or elevated cholesterol, although fludrocortisone, androgen excess, age, and the disease itself may also contribute.
Can long-term CAH steroid treatment weaken my bones?
Long-term exposure to high glucocorticoid doses can lower bone mineral density and, in severe cases, contribute to osteoporosis. Fracture risk is less certain and also depends on age, biological sex, nutrition, low sex hormone levels, and the type of medicine; longer-acting drugs such as dexamethasone or prednisolone may have a greater negative effect than hydrocortisone.
Should I reduce my hydrocortisone if I notice side effects?
No. People with classic CAH need prescribed glucocorticoid replacement to prevent adrenal crisis, and reducing or stopping it without medical guidance can be life-threatening. Your endocrinologist can review your dose and aim for the lowest effective prescribed amount while maintaining illness and emergency instructions.
What tests can monitor long-term complications of CAH steroid treatment?
Your care team may monitor blood pressure, weight, fasting glucose or HbA1c, a longer-term blood sugar test, and cholesterol levels. A DXA scan, a specialized x-ray that measures bone density, may be considered based on cumulative steroid exposure, fracture history, and other risk factors. Results such as 17-OHP should be interpreted with the timing of the blood draw and your overall clinical picture.
Does a high 17-OHP result mean my hydrocortisone dose should increase?
Not necessarily. 17-OHP is a hormone marker, and its result depends partly on when the blood was drawn relative to your medication; your endocrinologist also considers androgen levels, physical findings, weight, blood pressure, and how you feel. Do not increase the dose on your own.

Related questions

Can Non-Classic CAH Affect Fertility and Pregnancy? What to Do If You Miss a Dose of Hydrocortisone for CAH Is Prenatal Dexamethasone Safe for Babies With CAH? How Long Can You Live With CAH? Long-Term Prognosis Can TARTs Affect Fertility in Boys With Classic CAH?
Show more
How Does 11-Beta Deficiency Differ From 21-Hydroxylase CAH? Can Congenital Adrenal Hyperplasia Be Inherited? Carrier Risk How Does Classic CAH Affect Adult Height and Bone Age? Do I Need Treatment for Asymptomatic Non-Classic CAH? Should Girls With CAH Have Early Reconstructive Surgery? CAH Diet and Food Restrictions: What Should You Eat? When Should People With CAH Stress Dose During Exercise? What Should Be in My CAH Emergency Injection Kit? Checklist What Is the Difference Between Non-Classic CAH and PCOS? Can Premature Babies Have a False-Positive CAH Screen? How Is Classic CAH Medication Managed During Pregnancy? What Temperature Requires Stress Dosing for a Child With CAH? Do Infants With Salt-Wasting CAH Need Extra Salt Daily? What Should I Do if My Child Vomits a CAH Stress Dose?

Get notified when new evidence is published on Congenital adrenal hyperplasia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (27)
  1. 1

    Congenital Adrenal Hyperplasia.

    Fraga NR, Minaeian N, Kim MS

    Pediatrics in review 2024; (45(2)):74-84 doi:10.1542/pir.2022-005617.

    PMID: 38296783
  2. 2

    Longitudinal Assessment of Illnesses, Stress Dosing, and Illness Sequelae in Patients With Congenital Adrenal Hyperplasia.

    El-Maouche D, Hargreaves CJ, Sinaii N, et al.

    The Journal of clinical endocrinology and metabolism 2018; (103(6)):2336-2345 doi:10.1210/jc.2018-00208.

    PMID: 29584889
  3. 3

    Audit of management of children and adolescents with congenital adrenal hyperplasia as per recent Endocrine Society guidelines.

    S L, Krishna Prasad H, Ramjee B, et al.

    Pediatric endocrinology, diabetes, and metabolism 2023; (29(1)):10-15 doi:10.5114/pedm.2022.122547.

    PMID: 36734395
  4. 4

    Congenital adrenal hyperplasia: New biomarkers and adult treatments.

    Dreves B, Reznik Y, Tabarin A

    Annales d'endocrinologie 2023; (84(4)):472-480 doi:10.1016/j.ando.2023.01.008.

    PMID: 36842612
  5. 5

    Would Cortisol Measurements Be a Better Gauge of Hydrocortisone Replacement Therapy? Congenital Adrenal Hyperplasia as an Exemplar.

    Hindmarsh PC, Honour JW

    International journal of endocrinology 2020; (2020()):2470956 doi:10.1155/2020/2470956.

    PMID: 33299411
  6. 6

    Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline.

    Speiser PW, Arlt W, Auchus RJ, et al.

    The Journal of clinical endocrinology and metabolism 2018; (103(11)):4043-4088 doi:10.1210/jc.2018-01865.

    PMID: 30272171
  7. 7

    Cardiometabolic Aspects of Congenital Adrenal Hyperplasia.

    Krysiak R, Claahsen-van der Grinten HL, Reisch N, et al.

    Endocrine reviews 2025; (46(1)):80-148 doi:10.1210/endrev/bnae026.

    PMID: 39240753
  8. 8

    Treatment and Follow-up of Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency in Childhood and Adolescence

    Peltek Kendirci HN, Ünal E, Dündar İ, et al.

    Journal of clinical research in pediatric endocrinology 2025; (17(Suppl 1)):12-22 doi:10.4274/jcrpe.galenos.2024.2024-6-26-S.

    PMID: 39713876
  9. 9

    Cardiovascular Disease Risk Factors and Metabolic Morbidity in a Longitudinal Study of Congenital Adrenal Hyperplasia.

    Torky A, Sinaii N, Jha S, et al.

    The Journal of clinical endocrinology and metabolism 2021; (106(12)):e5247-e5257 doi:10.1210/clinem/dgab133.

    PMID: 33677504
  10. 10

    Cardiovascular and Metabolic Outcomes in Congenital Adrenal Hyperplasia: A Systematic Review and Meta-Analysis.

    Tamhane S, Rodriguez-Gutierrez R, Iqbal AM, et al.

    The Journal of clinical endocrinology and metabolism 2018; (103(11)):4097-4103 doi:10.1210/jc.2018-01862.

    PMID: 30272185
  11. 11

    Relationship between adipokines and androgens in children and young adults with congenital adrenal hyperplasia.

    Apsan J, Lekarev O, Thomas C, et al.

    Frontiers in endocrinology 2024; (15()):1433378 doi:10.3389/fendo.2024.1433378.

    PMID: 39175574
  12. 12

    Clinical Manifestations and Challenges in Adolescent and Adult Females With Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency.

    Engberg H, Nordenström A, Hirschberg AL

    The Journal of clinical endocrinology and metabolism 2025; (110(Supplement_1)):S37-S45 doi:10.1210/clinem/dgae696.

    PMID: 39836618
  13. 13

    Insulin Resistance in Congenital Adrenal Hyperplasia is Compensated for by Reduced Insulin Clearance.

    de Oliveira DM, Tura A, Vasques ACJ, et al.

    The Journal of clinical endocrinology and metabolism 2021; (106(4)):e1574-e1585 doi:10.1210/clinem/dgab010.

    PMID: 33421070
  14. 14

    Metabolic syndrome and cardiovascular morbidity in patients with congenital adrenal hyperplasia.

    Barbot M, Mazzeo P, Lazzara M, et al.

    Frontiers in endocrinology 2022; (13()):934675 doi:10.3389/fendo.2022.934675.

    PMID: 35979433
  15. 15

    Increased Cardiovascular and Metabolic Morbidity in Patients With 21-Hydroxylase Deficiency: A Swedish Population-Based National Cohort Study.

    Falhammar H, Frisén L, Hirschberg AL, et al.

    The Journal of clinical endocrinology and metabolism 2015; (100(9)):3520-8 doi:10.1210/JC.2015-2093.

    PMID: 26126207
  16. 16

    Blood Pressure in Children with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency.

    Balagamage C, Lawrence NR, Krone R, et al.

    Hormone research in paediatrics 2024; (97(4)):315-325 doi:10.1159/000533465.

    PMID: 37611560
  17. 17

    Bone Mineral Density in Adults With Congenital Adrenal Hyperplasia: A Systematic Review and Meta-Analysis.

    Rangaswamaiah S, Gangathimmaiah V, Nordenstrom A, Falhammar H

    Frontiers in endocrinology 2020; (11()):493 doi:10.3389/fendo.2020.00493.

    PMID: 32903805
  18. 18

    Increased Prevalence of Fractures in Congenital Adrenal Hyperplasia: A Swedish Population-based National Cohort Study.

    Falhammar H, Frisén L, Hirschberg AL, et al.

    The Journal of clinical endocrinology and metabolism 2022; (107(2)):e475-e486 doi:10.1210/clinem/dgab712.

    PMID: 34601607
  19. 19

    Bone mineral density determinants in adolescents and young adults with congenital adrenal hyperplasia.

    Navardauskaite R, Vanckaviciene A, Verkauskiene R

    Frontiers in pediatrics 2024; (12()):1456679 doi:10.3389/fped.2024.1456679.

    PMID: 39439446
  20. 20

    Effects of androgen excess and glucocorticoid exposure on bone health in adult patients with 21-hydroxylase deficiency.

    Auer MK, Paizoni L, Hofbauer LC, et al.

    The Journal of steroid biochemistry and molecular biology 2020; (204()):105734 doi:10.1016/j.jsbmb.2020.105734.

    PMID: 32784048
  21. 21

    Challenges in Adolescent and Adult Males With Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency.

    Claahsen-van der Grinten HL, Adriaansen BPH, Falhammar H

    The Journal of clinical endocrinology and metabolism 2025; (110(Supplement_1)):S25-S36 doi:10.1210/clinem/dgae718.

    PMID: 39836620
  22. 22

    Bone mineral density and fractures in congenital adrenal hyperplasia: Findings from the dsd-LIFE study.

    Riehl G, Reisch N, Roehle R, et al.

    Clinical endocrinology 2020; (92(4)):284-294 doi:10.1111/cen.14149.

    PMID: 31886890
  23. 23

    Glucocorticoid Regimens in the Treatment of Congenital Adrenal Hyperplasia: A Systematic Review and Meta-Analysis.

    Whittle E, Falhammar H

    Journal of the Endocrine Society 2019; (3(6)):1227-1245 doi:10.1210/js.2019-00136.

    PMID: 31187081
  24. 24

    Reduction in daily hydrocortisone dose improves bone health in primary adrenal insufficiency.

    Schulz J, Frey KR, Cooper MS, et al.

    European journal of endocrinology 2016; (174(4)):531-8 doi:10.1530/EJE-15-1096.

    PMID: 26811406
  25. 25

    Height Velocity Defined Metabolic Control in Children With Congenital Adrenal Hyperplasia Using Urinary Steroid GC-MS Analysis.

    Kamrath C, Wettstaedt L, Hartmann MF, Wudy SA

    The Journal of clinical endocrinology and metabolism 2019; (104(9)):4214-4224 doi:10.1210/jc.2019-00438.

    PMID: 31112272
  26. 26

    Treatment patterns and unmet needs in adults with classic congenital adrenal hyperplasia: A modified Delphi consensus study.

    Auchus RJ, Courtillot C, Dobs A, et al.

    Frontiers in endocrinology 2022; (13()):1005963 doi:10.3389/fendo.2022.1005963.

    PMID: 36465641
  27. 27

    Update on diagnosis and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

    White PC

    Current opinion in endocrinology, diabetes, and obesity 2018; (25(3)):178-184 doi:10.1097/MED.0000000000000402.

    PMID: 29718004

This page explains the possible long-term effects of glucocorticoid overtreatment in classic CAH for informational purposes only and does not constitute medical advice. Never reduce or stop your medication on your own; review dosing, monitoring, and emergency plans with your endocrinologist.